Information Provided By:
Fly News Breaks for June 8, 2015
LGND
Jun 8, 2015 | 08:39 EDT
Roth Capital believes that the data for Ligand's LGD-6972 was positive and impressive, as it showed dose dependent reductions in fasting plasma glucose and a strong safety profile, according to the firm. The firm expects the company to find a partner for the drug before a Phase II trial slated to take place next year. Roth keeps a $135 price target and Buy rating on Ligand.
News For LGND From the Last 2 Days
There are no results for your query LGND